Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Financing Activities (2022 - 2025)

Praxis Precision Medicines has reported Cash from Financing Activities over the past 4 years, most recently at $612.5 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $612.5 million for Q4 2025, up 438.4% from a year ago — trailing twelve months through Dec 2025 was $702.2 million (up 36.52% YoY), and the annual figure for FY2025 was $702.2 million, up 36.52%.
  • Cash from Financing Activities for Q4 2025 was $612.5 million at Praxis Precision Medicines, up from $6.8 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PRAX hit a ceiling of $612.5 million in Q4 2025 and a floor of $504000.0 in Q2 2022.
  • Median Cash from Financing Activities over the past 4 years was $18.1 million (2023), compared with a mean of $87.9 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 13724.4% in 2023 and later crashed 86.77% in 2025.
  • Praxis Precision Medicines' Cash from Financing Activities stood at $5.4 million in 2022, then decreased by 23.41% to $4.1 million in 2023, then surged by 2657.32% to $113.8 million in 2024, then soared by 438.4% to $612.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were $612.5 million (Q4 2025), $6.8 million (Q3 2025), and $28.6 million (Q2 2025) per Business Quant data.